This is a prospective study to evaluate the use of Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) to assess the effects of agents on tumor associated vasculature. Patients with cancer who are being treated with agents or procedures that may have an effect on the tumor associated vasculature will undergo PET and MRI scans prior to treatment as well as during treatment. PET scans will be used to assess changes in tumor blood flow, blood volume and glucose uptake while MRI will be used to assess changes in tumor vascular density. Findings by PET and MRI will be correlated with standard imaging techniques such as CT scan. This protocol will only be utilized in conjunction with other approved protocols that are evaluating agents or therapies with potential effects on tumor associated vasculature.

Condition	Treatment or Intervention	Phase
Neoplasm	Drug: 18-FDG  Drug: H2O-15  Drug: 11-CO	Phase II

Further Study Details: 

Expected Total Enrollment:  123

This is a prospective study to evaluate the use of Positron Emission Tomography (PET) and/or Magnetic Resonance Imaging (MRI) to assess the effects of agents on tumor associated vasculature. Patients with cancer who are being treated with agents or procedures that may have an effect on the tumor associated vasculature will undergo PET and/or MRI scans prior to treatment as well as during treatment. PET scans will be used to assess changes in tumor blood flow, blood volume and glucose uptake while MRI will be used to assess changes in tumor vascular density. Findings by PET and MRI will be correlated with standard imaging techniques such as CT scan. This protocol will only be utilized in conjunction with other approved protocols that are evaluating agents or therapies with potential effects on tumor associated vasculature.

Genders Eligible for Study:  Both

Criteria

INCLUSION CRITERIA:
All patients greater than 18 years old who are eligible for a treatment protocol evaluating a therapeutic modality which may have an effect on tumor associated vasculature.
Patients must have imageable disease by standard CT or MRI and at least one lesion measuring greater than 2 cm in diameter.
Patients must be willing to return to NIH for their imaging scans.
Patients must be able to sign informed consent.
EXCLUSION CRITERIA:
Patients must weigh greater than 136 kgs, which is the weight limit for the scanner tables.
Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required prior to enrollment.
Renal insufficiency as determined by a serum creatinine greater than 2.0.
History of sensitivity to contrast agents which cannot be controlled with premedication
Patients with pacemakers, cerebral aneurysm clips, shrapnel injury or implantable electronic devices

Maryland
      National Cancer Institute (NCI), 9000 Rockville Pike,  Bethesda,  Maryland,  20892,  United States; Recruiting

Study ID Numbers:  980163; 98-C-0163
Record last reviewed:  September 1, 2004
Last Updated:  March 30, 2005
Record first received:  November 3, 1999
ClinicalTrials.gov Identifier:  NCT00001709
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08